Tech Company Financing Transactions
Breye Therapeutics Funding Round
On 11/11/2022, Breye Therapeutics received $4 million in Seed funding from Novo Holdings, Sound Bioventures and BioInnovation Institute.
Transaction Overview
Company Name
Announced On
11/11/2022
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Seed
Investors
Novo Holdings (Lead Investor) (Jørgen Petersen)
Sound Bioventures (Lead Investor) (Johan Kördel)
Proceeds Purpose
The company intends to use the funds to expand its team and its pipeline across a broader range of ophthalmologic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Denmark, SC Undisclosed
USA
Denmark, SC Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Breye Therapeutics is a clinical stage clinical biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Breye has two novel and relevant small molecule oral therapies to address large unmet medical needs in both diabetic retinopathy (DR) and age-related macular degeneration (AMD)
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ulrik Mouritzen
Browse more venture capital transactions:
Prev: 11/11/2022: Brightside venture capital transaction
Next: 11/11/2022: Neotiv venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs